Name: Satoshi Matsusaka

Country: Japan

Affiliation:

Department of Gastroenterology,
Cancer Institute Hospital, Japanese foundation for cancer research

Phone no: +81-3-3520-0111

Fax: +81-3-3570-0343

Email: Send an Email


Address:

3-8-31 Ariake, Koto-ku,
Tokyo 135-8550, Japan

Research Interests:

Colorectal cancer, Gastric cancer, Chemotherapy, Biomarker, Circulating tumor cell, Circulation endothelial cell, Cellfree-DNA, Translational research.

Biography:

Memberships on Editorial Boards:

  • 2012-present    Full Member- American Society of Clinical Oncology
  • 2010-present    Professional of Medical oncology, - Japanese Society of Medical Oncology
  • 2006-present    Member, Japanese Society of Medical Oncology, Member, Japanese Cancer Association
  • 1998-present    Certified physician, Japan Surgical Society
  • 1994-present    Member, Japan Surgical Society

Publications:

  1. Management of allergic reactions to oxaliplatin in colorectal cancer patients.
  2. Genetic variations in immunomodulatory pathways to predict survival in patients with locoregional gastric cancer.
  3. Variations in genes regulating tumor-associated macrophages (TAMs) to predict outcomes of bevacizumab-based treatment in patients with metastatic colorectal cancer: Results from TRIBE and FIRE3 trials.
  4. Pharmacogenomics of fluorouracil-based chemotherapy toxicity.
  5. Variations in genes involved in immune response checkpoints and association with outcomes in patients with resected colorectal liver metastases.
  6. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer.
  7. A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid.
  8. Irinotecan monotherapy offers advantage over combination therapy with irinotecan plus cisplatin in second-line setting for treatment of advanced gastric cancer following failure of fluoropyrimidine-based regimens.
  9. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
  10. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.